Background: Despite data derived from observational studies, optimal anticoagulation
strategies have yet to be established for patients with nonvalvular atrial fibrillation and …

Background Considering that the current fixed dose of direct oral anticoagulants (DOACs)
might have insufficient anticoagulation effect for overweight patients, the aim of this study …

Background: It is unclear whether the overall effectiveness and safety of direct oral
anticoagulants (DOACs) are consistent in patients with nonvalvular atrial fibrillation (AF) and …

Background: Body Mass Index (BMI) is a risk factor for atrial fibrillation (AF). Few studies
have examined the relations between BMI and outcomes in patients with AF treated with …

Essentials• The association of body weight and patient‐important outcomes remains
unknown.• Phase III randomized controlled trials of direct oral anticoagulants (DOACs) were …

Importance In the Apixaban for Reduction of Stroke and Other Thromboembolic
Complications in Atrial Fibrillation (ARISTOTLE) trial, the standard dose of apixaban was 5 …

Background The ELDERCARE‐AF trial showed that low‐dose edoxaban benefits elderly
patients with nonvalvular atrial fibrillation considered ineligible for standard oral …

Atrial fibrillation (AF) is a cardiac condition characterized by an irregular heart rhythm, which
is increasingly prevalent in the modern era. All international guidelines strongly advise the …

Introduction Direct oral anticoagulant (DOAC) agents are established as the anticoagulation
strategy of choice for a variety of clinical risks. Despite this, uncertainty still exists with regard …

Background Apixaban and rivaroxaban are increasingly used for thromboembolism
prophylaxis in patients with non‐valvular atrial fibrillation (NVAF) and commonly in patients …